Yield10 Bioscience Announces Third Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- US stocks set for higher open as AI trade steadies; midterms in focus
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops more than 4% on talks aimed at ending US-Iran war
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
- Marvell agrees to acquire Lumentum in all-stock deal valued at $115B
- Cipher Digital posts Q3 revenue of $27M, logs first HPC lease income
- Binance sees spike in withdrawals as exchange returns online after $6.3 billion heist
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet
- Iran, Qatari mediators hold third day of talks to end US-Iran war
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Yield10 Bioscience, Inc. (YTEN) Tops Q3 EPS by 7c
November 12, 2020 4:39 PM ESTYield10 Bioscience, Inc. (NASDAQ: YTEN) reported Q3 EPS of ($0.87), $0.07 better than the analyst estimate of ($0.94). Revenue for the quarter came in at $204 thousand versus the consensus estimate of $240 thousand.
"We are very pleased with our strong progress across multiple fronts in the third quarter and beyond," said Oliver Peoples, Ph.D., President and Chief Executive Officer of Yield10 Bioscience. We completed harvesting for our 2020 field test program to evaluate novel yield and compositional traits in Camelina and... More



